Logo image of MRSN

MERSANA THERAPEUTICS INC (MRSN) Stock Fundamental Analysis

NASDAQ:MRSN - Nasdaq - US59045L1061 - Common Stock - Currency: USD

0.528  -0.03 (-5.21%)

Premarket: 0.5357 +0.01 (+1.46%)

Fundamental Rating

2

Overall MRSN gets a fundamental rating of 2 out of 10. We evaluated MRSN against 571 industry peers in the Biotechnology industry. MRSN may be in some trouble as it scores bad on both profitability and health. MRSN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MRSN has reported negative net income.
In the past year MRSN has reported a negative cash flow from operations.
In the past 5 years MRSN always reported negative net income.
MRSN had a negative operating cash flow in each of the past 5 years.
MRSN Yearly Net Income VS EBIT VS OCF VS FCFMRSN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M -200M

1.2 Ratios

MRSN has a Return On Assets of -44.02%. This is comparable to the rest of the industry: MRSN outperforms 51.69% of its industry peers.
The Return On Equity of MRSN (-7113.35%) is worse than 85.44% of its industry peers.
Industry RankSector Rank
ROA -44.02%
ROE -7113.35%
ROIC N/A
ROA(3y)-73.18%
ROA(5y)-55.6%
ROE(3y)-275.55%
ROE(5y)-180.25%
ROIC(3y)N/A
ROIC(5y)N/A
MRSN Yearly ROA, ROE, ROICMRSN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MRSN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRSN Yearly Profit, Operating, Gross MarginsMRSN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100K -200K -300K -400K

More info and screens

2

2. Health

2.1 Basic Checks

MRSN does not have a ROIC to compare to the WACC, probably because it is not profitable.
MRSN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MRSN has been increased compared to 5 years ago.
MRSN has a worse debt/assets ratio than last year.
MRSN Yearly Shares OutstandingMRSN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
MRSN Yearly Total Debt VS Total AssetsMRSN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

MRSN has an Altman-Z score of -7.75. This is a bad value and indicates that MRSN is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -7.75, MRSN is doing worse than 69.63% of the companies in the same industry.
MRSN has a Debt/Equity ratio of 13.35. This is a high value indicating a heavy dependency on external financing.
MRSN has a worse Debt to Equity ratio (13.35) than 85.61% of its industry peers.
Industry RankSector Rank
Debt/Equity 13.35
Debt/FCF N/A
Altman-Z -7.75
ROIC/WACCN/A
WACC11%
MRSN Yearly LT Debt VS Equity VS FCFMRSN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 2.35 indicates that MRSN has no problem at all paying its short term obligations.
The Current ratio of MRSN (2.35) is worse than 73.18% of its industry peers.
MRSN has a Quick Ratio of 2.35. This indicates that MRSN is financially healthy and has no problem in meeting its short term obligations.
MRSN's Quick ratio of 2.35 is on the low side compared to the rest of the industry. MRSN is outperformed by 72.11% of its industry peers.
Industry RankSector Rank
Current Ratio 2.35
Quick Ratio 2.35
MRSN Yearly Current Assets VS Current LiabilitesMRSN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

MRSN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 64.12%, which is quite impressive.
Looking at the last year, MRSN shows a very negative growth in Revenue. The Revenue has decreased by -14.70% in the last year.
MRSN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 28.33% yearly.
EPS 1Y (TTM)64.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)-14.7%
Revenue growth 3Y254.11%
Revenue growth 5Y28.33%
Sales Q2Q%63.65%

3.2 Future

The Earnings Per Share is expected to grow by 10.99% on average over the next years. This is quite good.
Based on estimates for the next years, MRSN will show a very strong growth in Revenue. The Revenue will grow by 23.55% on average per year.
EPS Next Y56.25%
EPS Next 2Y22.75%
EPS Next 3Y13.82%
EPS Next 5Y10.99%
Revenue Next Year-22.53%
Revenue Next 2Y-17.59%
Revenue Next 3Y4.94%
Revenue Next 5Y23.55%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
MRSN Yearly Revenue VS EstimatesMRSN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
MRSN Yearly EPS VS EstimatesMRSN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MRSN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MRSN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRSN Price Earnings VS Forward Price EarningsMRSN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRSN Per share dataMRSN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

A more expensive valuation may be justified as MRSN's earnings are expected to grow with 13.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.75%
EPS Next 3Y13.82%

More info and screens

0

5. Dividend

5.1 Amount

MRSN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MERSANA THERAPEUTICS INC

NASDAQ:MRSN (2/20/2025, 8:00:01 PM)

Premarket: 0.5357 +0.01 (+1.46%)

0.528

-0.03 (-5.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)02-26 2025-02-26/amc
Inst Owners94.28%
Inst Owner Change-9.57%
Ins Owners1.36%
Ins Owner Change0.96%
Market Cap61.06M
Analysts85
Price Target5.48 (937.88%)
Short Float %8.32%
Short Ratio1.74
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)17.67%
Min EPS beat(2)-14.37%
Max EPS beat(2)49.71%
EPS beat(4)3
Avg EPS beat(4)13.3%
Min EPS beat(4)-14.37%
Max EPS beat(4)49.71%
EPS beat(8)5
Avg EPS beat(8)9.15%
EPS beat(12)6
Avg EPS beat(12)-48.02%
EPS beat(16)6
Avg EPS beat(16)-40.62%
Revenue beat(2)1
Avg Revenue beat(2)-5.1%
Min Revenue beat(2)-74.22%
Max Revenue beat(2)64.02%
Revenue beat(4)2
Avg Revenue beat(4)-8.14%
Min Revenue beat(4)-74.22%
Max Revenue beat(4)64.02%
Revenue beat(8)2
Avg Revenue beat(8)-16.89%
Revenue beat(12)4
Avg Revenue beat(12)-3.11%
Revenue beat(16)4
Avg Revenue beat(16)-25.75%
PT rev (1m)-17.31%
PT rev (3m)-17.31%
EPS NQ rev (1m)-5.15%
EPS NQ rev (3m)12.72%
EPS NY rev (1m)-1.13%
EPS NY rev (3m)13.69%
Revenue NQ rev (1m)-0.45%
Revenue NQ rev (3m)-8.97%
Revenue NY rev (1m)-0.15%
Revenue NY rev (3m)24.99%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.75
P/FCF N/A
P/OCF N/A
P/B 58.21
P/tB 58.21
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)-0.83
FCFYN/A
OCF(TTM)-0.82
OCFYN/A
SpS0.3
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.02%
ROE -7113.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-73.18%
ROA(5y)-55.6%
ROE(3y)-275.55%
ROE(5y)-180.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 13.35
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.04%
Cap/Sales 1.49%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.35
Quick Ratio 2.35
Altman-Z -7.75
F-Score4
WACC11%
ROIC/WACCN/A
Cap/Depr(3y)151.69%
Cap/Depr(5y)110.08%
Cap/Sales(3y)546.39%
Cap/Sales(5y)339.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y56.25%
EPS Next 2Y22.75%
EPS Next 3Y13.82%
EPS Next 5Y10.99%
Revenue 1Y (TTM)-14.7%
Revenue growth 3Y254.11%
Revenue growth 5Y28.33%
Sales Q2Q%63.65%
Revenue Next Year-22.53%
Revenue Next 2Y-17.59%
Revenue Next 3Y4.94%
Revenue Next 5Y23.55%
EBIT growth 1Y59.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year58.27%
EBIT Next 3Y14.2%
EBIT Next 5YN/A
FCF growth 1Y-127.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-134.52%
OCF growth 3YN/A
OCF growth 5YN/A